PE20160173A1 - SALES DE DERIVADOS DE 2-AMINO-1-HIDROXIETIL-8-HIDROXIQUINOLIN-2(1H)-ONA QUE TIENEN ACTIVIDAD ANTAGONISTA DE RECEPTORES MUSCARINICOS ASI COMO ACTIVIDAD AGONISTA DEL RECEPTOR ß2 ADRENERGICO - Google Patents
SALES DE DERIVADOS DE 2-AMINO-1-HIDROXIETIL-8-HIDROXIQUINOLIN-2(1H)-ONA QUE TIENEN ACTIVIDAD ANTAGONISTA DE RECEPTORES MUSCARINICOS ASI COMO ACTIVIDAD AGONISTA DEL RECEPTOR ß2 ADRENERGICOInfo
- Publication number
- PE20160173A1 PE20160173A1 PE2016000066A PE2016000066A PE20160173A1 PE 20160173 A1 PE20160173 A1 PE 20160173A1 PE 2016000066 A PE2016000066 A PE 2016000066A PE 2016000066 A PE2016000066 A PE 2016000066A PE 20160173 A1 PE20160173 A1 PE 20160173A1
- Authority
- PE
- Peru
- Prior art keywords
- amino
- hydroxy
- hydroxyquinolin
- methyl
- hydroxyethyl
- Prior art date
Links
- -1 2-AMINO-1-HYDROXYETHYL-8-HYDROXYQUINOLIN-2 (1H) -ONE DERIVATIVE SALTS Chemical class 0.000 title abstract 5
- 102100039705 Beta-2 adrenergic receptor Human genes 0.000 title 1
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 title 1
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 title 1
- 239000000556 agonist Substances 0.000 title 1
- 230000003042 antagnostic effect Effects 0.000 title 1
- 108010014499 beta-2 Adrenergic Receptors Proteins 0.000 title 1
- 230000000694 effects Effects 0.000 title 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 abstract 2
- OCBFFGCSTGGPSQ-UHFFFAOYSA-N [CH2]CC Chemical compound [CH2]CC OCBFFGCSTGGPSQ-UHFFFAOYSA-N 0.000 abstract 2
- QUPDWYMUPZLYJZ-UHFFFAOYSA-N ethyl Chemical compound C[CH2] QUPDWYMUPZLYJZ-UHFFFAOYSA-N 0.000 abstract 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical class [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 abstract 2
- CVHZOJJKTDOEJC-UHFFFAOYSA-M 1,1-dioxo-1,2-benzothiazol-3-olate Chemical compound C1=CC=C2C([O-])=NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-M 0.000 abstract 1
- 101000977048 Streptomyces cinnamonensis Uncharacterized protein in mutB 3'region Proteins 0.000 abstract 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical class [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- ZXZKYYHTWHJHFT-UHFFFAOYSA-N quinoline-2,8-diol Chemical class C1=CC(=O)NC2=C1C=CC=C2O ZXZKYYHTWHJHFT-UHFFFAOYSA-N 0.000 abstract 1
- 230000000241 respiratory effect Effects 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-N sulfonic acid Chemical compound OS(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/15—Fumaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
- C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
- C07D275/06—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
SE REFIERE A SALES DE ADICION CRISTALINAS DE i) DERIVADOS DE 8-HIDROXIQUINOLIN-2(1H)-ONA DE FORMULA (I) DONDE R1, R2 Y R3 SON CADA UNO H O ALQUILO C1-2; R4 ES H, OH, ENTRE OTROS; R5 Y R6 SON CADA UNO TIENILO, FENILO, ENTRE OTROS; V Y W SON -N-, -S- O -C(O)-; n Y m SON DE 0 A 4; Y ii) UN ACIDO DICARBOXILICO, UN ACIDO SULFONICO O UNA SULFIMIDA, O UN SOLVATO FARMACEUTICAMENTE ACEPTABLE DE LAS MISMAS. SON PREFERIDAS LAS SALES: SACARINATO DE HIDROXI(DI-2-TIENIL)ACETATO DE TRANS-4-[{3-[5-({[(2R)-2-HIDROXI-2-(8-HIDROXI-2-OXO-1,2-DIHIDROQUINOLIN-5-IL)ETIL]AMINO}METIL)-1H-1,2,3-BENZOTRIAZOL-1-IL]PROPIL}(METIL)AMINO]CICLOHEXILO; FUMARATO DE HIDROXI(DI-2-TIENIL)ACETATO DE TRANS-4-[{3-[6-({[(2R)-2-HIDROXI-2-(8-HIDROXI-2-OXO-1,2-DIHIDROQUINOLIN-5-IL)ETIL]AMINO}METIL)-2-OXO-1,3-BENZOTIAZOL-3(2H)-IL]PROPIL}(METIL)AMINO]CICLOHEXILO. DICHAS SALES SON UTILES PARA EL TRATAMIENTO DE ENFERMEDADES RESPIRATORIAS
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13382304 | 2013-07-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20160173A1 true PE20160173A1 (es) | 2016-04-13 |
Family
ID=48917474
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2016000066A PE20160173A1 (es) | 2013-07-25 | 2014-07-24 | SALES DE DERIVADOS DE 2-AMINO-1-HIDROXIETIL-8-HIDROXIQUINOLIN-2(1H)-ONA QUE TIENEN ACTIVIDAD ANTAGONISTA DE RECEPTORES MUSCARINICOS ASI COMO ACTIVIDAD AGONISTA DEL RECEPTOR ß2 ADRENERGICO |
Country Status (36)
| Country | Link |
|---|---|
| US (1) | US9579316B2 (es) |
| EP (1) | EP3024489B1 (es) |
| JP (1) | JP6374962B2 (es) |
| KR (1) | KR102338155B1 (es) |
| CN (2) | CN105492027A (es) |
| AR (1) | AR097079A1 (es) |
| AU (1) | AU2014295028B2 (es) |
| BR (1) | BR112016001295B1 (es) |
| CA (1) | CA2917596C (es) |
| CL (1) | CL2016000187A1 (es) |
| CR (1) | CR20160043A (es) |
| CY (1) | CY1122920T1 (es) |
| DK (1) | DK3024489T3 (es) |
| DO (1) | DOP2016000011A (es) |
| EA (1) | EA035436B1 (es) |
| ES (1) | ES2788627T3 (es) |
| HR (1) | HRP20200670T1 (es) |
| HU (1) | HUE049441T2 (es) |
| IL (1) | IL243173B (es) |
| LT (1) | LT3024489T (es) |
| MX (1) | MX360837B (es) |
| MY (1) | MY184681A (es) |
| NI (1) | NI201600012A (es) |
| NZ (1) | NZ715128A (es) |
| PE (1) | PE20160173A1 (es) |
| PH (1) | PH12016500125A1 (es) |
| PL (1) | PL3024489T3 (es) |
| PT (1) | PT3024489T (es) |
| RS (1) | RS60185B1 (es) |
| SG (1) | SG11201510682YA (es) |
| SI (1) | SI3024489T1 (es) |
| SM (1) | SMT202000185T1 (es) |
| TW (1) | TWI641373B (es) |
| UY (1) | UY35678A (es) |
| WO (1) | WO2015011244A1 (es) |
| ZA (1) | ZA201509203B (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2386555A1 (en) | 2010-05-13 | 2011-11-16 | Almirall, S.A. | New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities |
| EP2592078A1 (en) | 2011-11-11 | 2013-05-15 | Almirall, S.A. | New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities |
| CN105142673B8 (zh) | 2012-12-18 | 2018-02-16 | 阿尔米雷尔有限公司 | 具有β2肾上腺素能激动剂及M3毒蕈碱拮抗剂活性的新型环己基和奎宁环基氨基甲酸酯衍生物 |
| US9757395B2 (en) | 2012-12-20 | 2017-09-12 | Otitopic Inc. | Dry powder inhaler and methods of use |
| US9757529B2 (en) | 2012-12-20 | 2017-09-12 | Otitopic Inc. | Dry powder inhaler and methods of use |
| TWI643853B (zh) | 2013-02-27 | 2018-12-11 | 阿爾米雷爾有限公司 | 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類 |
| WO2014178891A1 (en) | 2013-04-30 | 2014-11-06 | Otitopic Inc. | Dry powder formulations and methods of use |
| TWI641373B (zh) | 2013-07-25 | 2018-11-21 | 阿爾米雷爾有限公司 | 具有蕈毒鹼受體拮抗劑和β２腎上腺素受體促效劑二者之活性的２－胺基－１－羥乙基－８－羥基喹啉－２（１Ｈ）－酮衍生物之鹽 |
| TW201517906A (zh) * | 2013-07-25 | 2015-05-16 | Almirall Sa | 含有ｍａｂａ化合物和皮質類固醇之組合 |
| TW201617343A (zh) | 2014-09-26 | 2016-05-16 | 阿爾米雷爾有限公司 | 具有β２腎上腺素促效劑及Ｍ３蕈毒拮抗劑活性之新穎雙環衍生物 |
| EP3375781A4 (en) * | 2015-07-21 | 2019-01-09 | Sichuan Haisco Pharmaceutical Co., Ltd. | BENZORING DERIVATIVE WITH B2 RECEPTOR AGONIST AND M3 RECEPTOR ANTAGONIST ACTIVITIES AND USE THEREOF IN MEDICINE |
| CN106554350B (zh) * | 2015-09-29 | 2019-12-20 | 四川海思科制药有限公司 | 具有β2激动活性的苯并杂环衍生物及其制法和应用 |
| TW201835041A (zh) * | 2017-02-17 | 2018-10-01 | 印度商托仁特生技有限公司 | 具β-腎上腺素促效劑及抗蕈毒活性化合物 |
| CN115919780A (zh) | 2017-09-22 | 2023-04-07 | 维克图拉公司 | 含有硬脂酸镁的干粉组合物 |
| US10786456B2 (en) | 2017-09-22 | 2020-09-29 | Otitopic Inc. | Inhaled aspirin and magnesium to treat inflammation |
| WO2020244452A1 (zh) * | 2019-06-06 | 2020-12-10 | 中国医药研究开发中心有限公司 | 具有β 2受体激动及M受体拮抗活性的杂环衍生物及其医药用途 |
| KR20230079111A (ko) * | 2020-09-28 | 2023-06-05 | 치아타이 티안큉 파마수티컬 그룹 주식회사 | 융합된 삼환계 유도체 및 이의 약학적 적용 |
| WO2023179758A1 (zh) * | 2022-03-25 | 2023-09-28 | 正大天晴药业集团股份有限公司 | 稠合三并环衍生物或其可药用盐的结晶 |
Family Cites Families (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1212742B (it) | 1983-05-17 | 1989-11-30 | Dompe Farmaceutici Spa | Derivati dibenzo [1,4]diazepinonici pirido [1,4] benzodiazepinonici,pirido [1,5] benzodiazepinonici e loro attivita' farmacologica |
| ATE25966T1 (de) | 1983-09-26 | 1987-04-15 | Magis Farmaceutici | Aminocyclohexanol-derivate mit expektoranter wirkung, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen. |
| EP1078629A3 (en) | 1989-09-07 | 2001-05-23 | Glaxo Group Limited | Use of Salmeterol and salts for the treatment of inflammation and allergy |
| GB9020051D0 (en) | 1990-09-13 | 1990-10-24 | Pfizer Ltd | Muscarinic receptor antagonists |
| WO1998009632A1 (en) | 1996-09-06 | 1998-03-12 | Merck & Co., Inc. | Methods and compositions for treating preterm labor |
| SE9704644D0 (sv) | 1997-12-12 | 1997-12-12 | Astra Ab | New use |
| US6673908B1 (en) | 1999-02-22 | 2004-01-06 | Nuvelo, Inc. | Tumor necrosis factor receptor 2 |
| CA2376275A1 (en) | 1999-08-20 | 2001-03-01 | Michael John Ricks | Fungicidal heterocyclic aromatic amides and their compositions, methods of use and preparation |
| US6806314B2 (en) | 2003-02-03 | 2004-10-19 | Ppg Industries Ohio, Inc. | Coating of Hydroxy-functional polymer(s), crosslinker, and 1,3- and 1,4-cyclohexane dimethanols |
| PE20040950A1 (es) | 2003-02-14 | 2005-01-01 | Theravance Inc | DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS |
| WO2004089892A2 (en) | 2003-04-01 | 2004-10-21 | Theravance, Inc. | Diarylmethyl and related compounds having beta2 andrenergic receptor agonist and muscarinic receptor antagonist activity |
| ATE435862T1 (de) | 2003-05-28 | 2009-07-15 | Theravance Inc | Azabicycloalkanverbindungen als muscarinrezeptor antagonisten |
| US7320990B2 (en) | 2004-02-13 | 2008-01-22 | Theravance, Inc. | Crystalline form of a biphenyl compound |
| DE102004024453A1 (de) | 2004-05-14 | 2006-01-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue langwirksame Bronchodilatoren zur Behandlung von Atemwegserkrankungen |
| ES2251867B1 (es) | 2004-06-21 | 2007-06-16 | Laboratorios Almirall S.A. | Nuevos derivados de piridazin-3(2h)-ona. |
| TWI374883B (en) | 2004-08-16 | 2012-10-21 | Theravance Inc | Crystalline form of a biphenyl compound |
| EP1833822A2 (en) | 2004-08-16 | 2007-09-19 | Theravance, Inc. | Compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity |
| JP2008510014A (ja) | 2004-08-16 | 2008-04-03 | セラヴァンス， インコーポレーテッド | β２アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有する化合物 |
| EP1924553A1 (en) | 2005-08-08 | 2008-05-28 | Argenta Discovery Limited | Bicyclo[2.2.]hept-7-ylamine derivatives and their uses |
| GB0602778D0 (en) | 2006-02-10 | 2006-03-22 | Glaxo Group Ltd | Novel compound |
| NZ570693A (en) | 2006-03-20 | 2011-02-25 | Pfizer Ltd | Amine derivatives |
| GB0613154D0 (en) | 2006-06-30 | 2006-08-09 | Novartis Ag | Organic Compounds |
| GB0702384D0 (en) | 2007-02-07 | 2007-03-21 | Argenta Discovery Ltd | Chemical compounds |
| WO2008017827A2 (en) | 2006-08-08 | 2008-02-14 | Argenta Discovery Limited | Azole and thiazole derivatives and their uses |
| EP1894568A1 (en) | 2006-08-31 | 2008-03-05 | Novartis AG | Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases |
| BRPI0719270A2 (pt) | 2006-10-04 | 2014-03-11 | Pfizer Ltd | Derivados de sulfonamida como agonistas adrenérgicos e antagonistas muscarínicos |
| GB0700972D0 (en) | 2007-01-18 | 2007-02-28 | Imp Innovations Ltd | Treatment of inflammatory disease |
| WO2008096129A1 (en) | 2007-02-07 | 2008-08-14 | Argenta Discovery Ltd | Nitrogen containing hetrocyclic compounds useful as bifunctional modulators of m3 receptors and beta- 2 receptors |
| GB0702413D0 (en) | 2007-02-07 | 2007-03-21 | Argenta Discovery Ltd | New chemical compounds |
| WO2008149110A1 (en) | 2007-06-08 | 2008-12-11 | Argenta Discovery Limited | Bicyclor [2.2.1] hept-7-ylamine derivatives and their use in the treatment of diseases and conditions in which m3 muscarinic receptor activity and beta-adrenergic activity are implicated |
| PE20090907A1 (es) | 2007-07-21 | 2009-08-05 | Boehringer Ingelheim Int | Nuevos medicamentos pulverulentos que contienen tiotropio y salmeterol, asi como lactosa como excipiente |
| WO2009017813A1 (en) * | 2007-08-02 | 2009-02-05 | Teva Pharmaceutical Industries Ltd. | O-desmethyl venlafaxine saccharinate |
| PT2242759E (pt) | 2008-02-06 | 2012-12-17 | Astrazeneca Ab | Compostos |
| CN101544572B (zh) | 2008-03-26 | 2013-03-20 | 连云港恒邦医药科技有限公司 | 一种氨溴索衍生物及其制备方法 |
| GB0808708D0 (en) | 2008-05-13 | 2008-06-18 | Astrazeneca Ab | New compounds 274 |
| EP2303266A4 (en) * | 2008-06-20 | 2015-01-21 | Astrazeneca Ab | PHARMACEUTICAL COMPOSITION COMPRISING A 4-HYDROXY-2-OXO-2,3-DIHYDRO-1,3-BENZOTHIAZOL-7-YLE COMPOUND FOR THE MODULATION OF BETA-2-ADRENORECEPTOR ACTIVITY |
| US8263623B2 (en) | 2008-07-11 | 2012-09-11 | Pfizer Inc. | Triazol derivatives useful for the treatment of diseases |
| WO2010015792A1 (en) | 2008-08-06 | 2010-02-11 | Argenta Discovery Limited | Nitrogen containing heterocyclic compounds useful as bifunctional modulators of m3 receptors and beta-2 receptors |
| EP2196465A1 (en) | 2008-12-15 | 2010-06-16 | Almirall, S.A. | (3-oxo)pyridazin-4-ylurea derivatives as PDE4 inhibitors |
| ES2635358T3 (es) | 2009-04-23 | 2017-10-03 | Theravance Respiratory Company, Llc | Compuestos de diamina que tienen actividad antagonista del receptor muscarínico y agonista del receptor beta2 adrenérgico |
| MX2011011446A (es) | 2009-04-30 | 2011-11-18 | Teijin Pharma Ltd | Compuestos de sal de amonio cuaternario. |
| GB0913345D0 (en) | 2009-07-31 | 2009-09-16 | Astrazeneca Ab | New combination 802 |
| GB201002612D0 (en) * | 2010-02-16 | 2010-03-31 | Jagotec Ag | Improvements in or relating to organic compounds |
| EP2386555A1 (en) | 2010-05-13 | 2011-11-16 | Almirall, S.A. | New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities |
| ITRM20110083U1 (it) | 2010-05-13 | 2011-11-14 | De La Cruz Jose Antonio Freire | Piastra per la costruzione di carrelli per aeroplani |
| AR083115A1 (es) | 2010-09-30 | 2013-01-30 | Theravance Inc | Sales oxalato cristalinas de un compuesto diamida |
| GB201021992D0 (en) | 2010-12-23 | 2011-02-02 | Astrazeneca Ab | Compound |
| GB201021979D0 (en) | 2010-12-23 | 2011-02-02 | Astrazeneca Ab | New compound |
| PE20141614A1 (es) | 2011-06-10 | 2014-11-20 | Chiesi Farma Spa | Compuestos con actividad antagonista de los receptores muscarinicos y actividad agonista del receptor beta2 adrenergico |
| CN103547575B (zh) | 2011-06-10 | 2016-08-17 | 奇斯药制品公司 | 具有毒蕈碱受体拮抗剂和β2肾上腺素能受体激动剂活性的化合物 |
| UA116622C2 (uk) | 2011-11-11 | 2018-04-25 | Аллерган, Інк. | Похідні 4-прегенен-11ss-17-21-тріол-3,20-діону для лікування хвороб очей |
| MX351299B (es) | 2011-11-11 | 2017-10-10 | Pfizer | 2-tiopirimidinonas. |
| EP2592077A1 (en) | 2011-11-11 | 2013-05-15 | Almirall, S.A. | New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities |
| EP2776038B1 (en) | 2011-11-11 | 2018-01-10 | Gilead Apollo, LLC | Acc inhibitors and uses thereof |
| EP2592078A1 (en) | 2011-11-11 | 2013-05-15 | Almirall, S.A. | New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities |
| BR112015012746A2 (pt) | 2012-12-06 | 2017-07-11 | Chiesi Farm Spa | compostos que possuem atividade de antagonista de receptores muscarínicos e agonista de receptores beta2-adrenérgicos |
| PE20151216A1 (es) | 2012-12-06 | 2015-09-08 | Chiesi Farma Spa | Compuestos con actividad antagonista de los receptores muscarinicos y actividad agonista del receptor beta2 adrenergico |
| CN105142673B8 (zh) | 2012-12-18 | 2018-02-16 | 阿尔米雷尔有限公司 | 具有β2肾上腺素能激动剂及M3毒蕈碱拮抗剂活性的新型环己基和奎宁环基氨基甲酸酯衍生物 |
| TWI643853B (zh) | 2013-02-27 | 2018-12-11 | 阿爾米雷爾有限公司 | 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類 |
| TW201440768A (zh) | 2013-02-27 | 2014-11-01 | Almirall Sa | 雙毒蕈鹼拮抗劑-β2腎上腺素促效劑複合物及皮質類固醇之組合物 |
| TWI641373B (zh) | 2013-07-25 | 2018-11-21 | 阿爾米雷爾有限公司 | 具有蕈毒鹼受體拮抗劑和β２腎上腺素受體促效劑二者之活性的２－胺基－１－羥乙基－８－羥基喹啉－２（１Ｈ）－酮衍生物之鹽 |
| TW201517906A (zh) | 2013-07-25 | 2015-05-16 | Almirall Sa | 含有ｍａｂａ化合物和皮質類固醇之組合 |
| TW201617343A (zh) | 2014-09-26 | 2016-05-16 | 阿爾米雷爾有限公司 | 具有β２腎上腺素促效劑及Ｍ３蕈毒拮抗劑活性之新穎雙環衍生物 |
-
2014
- 2014-07-22 TW TW103125077A patent/TWI641373B/zh not_active IP Right Cessation
- 2014-07-24 CA CA2917596A patent/CA2917596C/en active Active
- 2014-07-24 PT PT147475545T patent/PT3024489T/pt unknown
- 2014-07-24 KR KR1020167002012A patent/KR102338155B1/ko not_active Expired - Fee Related
- 2014-07-24 HU HUE14747554A patent/HUE049441T2/hu unknown
- 2014-07-24 PE PE2016000066A patent/PE20160173A1/es unknown
- 2014-07-24 CN CN201480042033.0A patent/CN105492027A/zh active Pending
- 2014-07-24 LT LTEP14747554.5T patent/LT3024489T/lt unknown
- 2014-07-24 HR HRP20200670TT patent/HRP20200670T1/hr unknown
- 2014-07-24 JP JP2016528538A patent/JP6374962B2/ja active Active
- 2014-07-24 DK DK14747554.5T patent/DK3024489T3/da active
- 2014-07-24 SM SM20200185T patent/SMT202000185T1/it unknown
- 2014-07-24 SG SG11201510682YA patent/SG11201510682YA/en unknown
- 2014-07-24 RS RS20200497A patent/RS60185B1/sr unknown
- 2014-07-24 CN CN202011250238.1A patent/CN112321579A/zh active Pending
- 2014-07-24 EP EP14747554.5A patent/EP3024489B1/en active Active
- 2014-07-24 ES ES14747554T patent/ES2788627T3/es active Active
- 2014-07-24 PL PL14747554T patent/PL3024489T3/pl unknown
- 2014-07-24 SI SI201431533T patent/SI3024489T1/sl unknown
- 2014-07-24 WO PCT/EP2014/065965 patent/WO2015011244A1/en not_active Ceased
- 2014-07-24 EA EA201600128A patent/EA035436B1/ru not_active IP Right Cessation
- 2014-07-24 BR BR112016001295-0A patent/BR112016001295B1/pt not_active IP Right Cessation
- 2014-07-24 MX MX2016000397A patent/MX360837B/es active IP Right Grant
- 2014-07-24 NZ NZ715128A patent/NZ715128A/en not_active IP Right Cessation
- 2014-07-24 US US14/906,991 patent/US9579316B2/en not_active Expired - Fee Related
- 2014-07-24 AU AU2014295028A patent/AU2014295028B2/en not_active Ceased
- 2014-07-24 MY MYPI2016700228A patent/MY184681A/en unknown
- 2014-07-25 UY UY35678A patent/UY35678A/es not_active Application Discontinuation
- 2014-07-25 AR ARP140102789A patent/AR097079A1/es not_active Application Discontinuation
-
2015
- 2015-12-17 ZA ZA2015/09203A patent/ZA201509203B/en unknown
- 2015-12-17 IL IL24317315A patent/IL243173B/en active IP Right Grant
-
2016
- 2016-01-12 DO DO2016000011A patent/DOP2016000011A/es unknown
- 2016-01-19 PH PH12016500125A patent/PH12016500125A1/en unknown
- 2016-01-20 NI NI201600012A patent/NI201600012A/es unknown
- 2016-01-22 CR CR20160043A patent/CR20160043A/es unknown
- 2016-01-25 CL CL2016000187A patent/CL2016000187A1/es unknown
-
2020
- 2020-04-13 CY CY20201100343T patent/CY1122920T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20160173A1 (es) | SALES DE DERIVADOS DE 2-AMINO-1-HIDROXIETIL-8-HIDROXIQUINOLIN-2(1H)-ONA QUE TIENEN ACTIVIDAD ANTAGONISTA DE RECEPTORES MUSCARINICOS ASI COMO ACTIVIDAD AGONISTA DEL RECEPTOR ß2 ADRENERGICO | |
| PE20151602A1 (es) | SALES DE DERIVADOS DE 2-AMINO-1-HIDROXIETIL-8-HIDROXIQUINOLIN-2(1H)-ONA QUE TIENEN ACTIVIDAD AGONISTA DEL RECEPTOR B(beta)2 ADRENERGICO ASI COMO ACTIVIDAD ANTAGONISTA DEL RECEPTOR MUSCARINICO M3 | |
| PE20141232A1 (es) | Nuevos derivados de ciclohexilamina que tienen actividad como agonistas adrenergicos �2 y como antagonistas muscarinicos m3 | |
| CY1120258T1 (el) | Ενωσεις ετεροδικυκλο-υποκατεστημενης-[1,2,4]τριαζολο [1,5-c]κιναζολιν-5-αμινης καταλληλες για αγωγη ή προληψη διαταραχων του κεντρικου νευρικου συστηματος | |
| PE20141231A1 (es) | Nuevos derivados de ciclohexilamina que tienen actividad como agonistas adrenergicos �2 y como antagonistas muscarinicos m3 | |
| EA201591537A1 (ru) | Производные бензотиофена и композиции, их содержащие, в качестве селективных супрессоров эстрогеновых рецепторов | |
| PE20151001A1 (es) | Alcoxipirazoles como activadores de guanilato ciclasa soluble | |
| MY194461A (en) | N-[2-(1-benzylpiperidin-4-yl)4-(pyrazin-2-yl)-piperazine-1-carboxamide derivatives and related compounds as muscarinic receptor 4 (m4) antagonists for treating neurological diseases | |
| CO6491058A2 (es) | Derivados de oxazina y su uso como inhibidores de bace para el tratamiento de trastornos neurológicos | |
| PE20141228A1 (es) | Derivados de pirrolopirimidina y purina | |
| AR060535A1 (es) | Pirido-piridazinonas y ftalazinonas como antagonistas duales de los receptores h1 y h3 de histamina | |
| PE20150774A1 (es) | Aminoquinolinas como inhibidores de cinasa | |
| PE20150399A1 (es) | Nuevos derivados de pirrol, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
| PE20141167A1 (es) | Piridopirazinas sustituidas como inhibidores novedosos de ptk | |
| PE20110929A1 (es) | Sal mesilato de 5-(2-{[6-(2,2-difluoro-2-feniletoxi) hexil] amino}-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona como agonista del receptor 2 adrenergico | |
| DOP2013000243A (es) | Inhibidores sustituidos de acetil-coa carboxilasa | |
| CO2017000438A2 (es) | Ácidos carboxílicos heterocíclicos como activadores de guanilato ciclasa soluble | |
| HK1220386A1 (zh) | Ep4受体拮抗剂在软骨疾病的治疗中的用途 | |
| PE20151060A1 (es) | Nuevos derivados de pirazina como agonistas del receptor cb2 | |
| CL2014002847A1 (es) | Compuestos triazolo derivados, inhibidores de pde10; procedimiento de preparacion; uso para el tratamiento y/o profilaxis de trastornos psicoticos, esquizofrenia, ansiedad, adicciona a drogas, enfermedad de parkinson, entre otras. | |
| UY35551A (es) | Derivados heteroarilos como inhibidores de aldosterona sintasa | |
| AR067648A1 (es) | Derivados de 2-aza-biciclo [2,2,2]octano, uso de los mismos y composiciones farmaceuticas que los contienen | |
| PE20150629A1 (es) | Derivados de etinilo como moduladores de la actividad del receptor de mglur5 | |
| MX339302B (es) | 3-(quinolin-6-il-tio)-[1,2,4]-triazolo-[4,3-a]-piridinas 6-sustituidas como cinasas de tirosina. | |
| CL2016001348A1 (es) | Forma cristalina de clorhidrato de (s)-(2-(6-cloro-7-metil-1h-benzo[d]imidazol-2-il)-2-metilpirrolidin-1-il)(5-metoxi-2-(2h-1,2,3-triazol-2-il)fenil)metanona; composición farmacéutica que la comprende; y su uso para el tratamiento o prevención de trastornos del sueño, tales como disomnias, parasomnias, entre otras. |